The new B7s: Playing a pivotal role in tumor immunity

Journal of Immunotherapy

Volumn 30, Issue 3, 2007, Pages 251-260

  Flies, Dallas B ^a,b   Chen, Lieping ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B7 DC; B7 H1; B7 H2; B7 H3; B7 H4; Immunotherapy; Tumor immunity

Indexed keywords

B7 ANTIGEN; B7 DC ANTIGEN; B7 H1 ANTIGEN; B7 H2 ANTIGEN; B7 H3 ANTIGEN; B7 H4 ANTIGEN; CANCER VACCINE; CD279 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B7 H1; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; AUTOIMMUNITY; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLON CARCINOMA; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; EXPRESSED SEQUENCE TAG; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MELANOMA; MOUTH CARCINOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION;

ANTIGENS, CD80; HUMANS; IMMUNITY; IMMUNOTHERAPY; NEOPLASMS; STROMAL CELLS;

EID: 34247157223     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31802e085a     Document Type: Review

References (38)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169:1042-1049.
2. Freedman AS, Freeman GJ, Rhynhart K, et al. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991;137:429-437.
3. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA. 1990;87:5031-5035.
4. Yokochi T, Holly RD, Clark EA. B lymphoblast antigen (BB-1) expressed on epstein-barr virus-activated B cell blasts, B lymphoblastoid cell lines, and burkitt's lymphomas. J Immunol. 1982;128:823-827.
5. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2001;2:203-209.
6. Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect. 2004;6:759-766.
7. Wang S, Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol. 2004;1:37-42.
8. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548.
9. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29-53.
10. Carreno BM, Carter LL, Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol. 2005;5:424-430.
11. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol. 2000;12:589-596.
12. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238.
13. Gattinoni L, Powell DJ, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
14. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
15. Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 2001;193:839-846.
16. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268.
17. Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. J Mol Med. 2005;83:193-202.
18. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med. 2003;81:281-287.
19. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-347.
20. He XH, Liu Y, Xu LH, et al. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sin (Shanghai). 2004;36:284-289.
21. Radhakrishnan S, Nguyen LT, Ciric B, et al. Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res. 2004;64:4965-4972.
22. Zhu B, Guleria I, Khosroshahi A, et al. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006;176:3480-3489.
23. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63-69.
24. Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003;198:71-78.
25. Matsumoto K, Inoue H, Nakano T, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol. 2004;172:2530-2541.
26. Tsushima F, Iwai H, Otsuki N, et al. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol. 2003;33:2773-2782.
27. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 1999;11:423-432.
28. Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell costimulation through B7RP-1 and ICOS. Nature. 1999;402:827-832.
29. Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood. 2000;96:2808-2813.
30. Brodie D, Collins AV, Iaboni A, et al. LICOS, a primordial costimulatory ligand? Curr Biol. 2000;10:333-336.
31. Mages HW, Hutloff A, Heuck C, et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol. 2000;30:1040-1047.
32. Grimbacher B, Warnatz K, Peter HH. The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity. Curr Opin Allergy Clin Immunol. 2003;3:409-419.
33. Mak TW, Shahinian A, Yoshinaga SK, et al. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. Nat Immunol. 2003;4:765-772.
34. Tamura H, Dan K, Tamada K, et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. 2005;11:5708-5717.
35. Richter G, Burdach S. ICOS: a new costimulatory ligand/receptor pair and its role in T-cell activion. Onkologie. 2004;27:91-95.
36. Liu X, Bai XF, Wen J, et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med. 2001;194:1339-1348.
37. Wallin JJ, Liang L, Bakardjiev A, et al. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol. 2001;167:132-139.
38. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells. J Immunol. 2002;169:3676-3685.